Differential Effects of BTK Inhibitors Ibrutinib and Zanubrutinib on NK Cell Effector Function in Patients With Mantle Cell Lymphoma

Haematologica - Italy
doi 10.3324/haematol.2019.220590
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Expanding Horizons in the Treatment of Mantle Cell Lymphoma: Ibrutinib a Novel BTK-targeting Inhibitor

International Journal of Basic & Clinical Pharmacology
2014English

Ibrutinib Plus Palbociclib Has Efficacy in Mantle Cell Lymphoma

Cancer Discovery
Oncology
2019English

Long-Term Outcomes and Mutation Profiling of Patients With Mantle Cell Lymphoma (MCL) Who Discontinued Ibrutinib

British Journal of Haematology
Hematology
2018English

Novel Chemotherapy-Free Combination Regimen for Ibrutinib-Resistant Mantle Cell Lymphoma

British Journal of Haematology
Hematology
2017English

The BTK Inhibitor CC-292 Shows Activity in Mantle Cell Lymphoma and Synergizes With Lenalidomide and NIK Inhibitors Depending on the NF-κB Mutational Status

Haematologica
Hematology
2017English

Venetoclax as a Single Agent and in Combination With PI3K-MTOR1/2 Kinase Inhibitors Against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma

British Journal of Haematology
Hematology
2018English

Online Education Significantly Improved the Competence of Hematologists/Oncologists and Nurses Regarding the Use of BTK Inhibitors for Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy